CD19 and diffuse large B-cell lymphoma: The researchers at BCM have attempted to simultaneously infuse first- and second-generation CAR-T cells targeting CD19 into patients with active FL or DLBCL; still no clinical benefit was observed, but CAR including CD28 costimulatory domains led to enhanced in vivo expansion and the persistence of CAR-T cells has been demonstrated (Savoldo et al., 2011).